Westminster, CO, April 12, 2018 – Flagship Biosciences’ cTA® and decision support platform will be featured in four scientific poster presentations at the American Association for Cancer Research (AACR) Annual Meeting, April 14-18, 2018, in Chicago.
As the leading partner for drug developers investigating tissue-based biomarkers, Flagship applies computational tissue analysis to provide quantitative, contextual data that drives more confident clinical trial decisions. Flagship scientists will present the company’s latest developments in immune and tumor cell analysis.
Scientific poster presentation details:
- Analysis of Multiplexed Immunotherapy Targets and Secreted Ligands Using Computational Tumor Microenvironment Profiling,
Monday, Apr. 16, 8 am – 12 pm, Poster Section 32, #1720.
- Computational Analysis of Multiplexed Immunohistochemistry for Understanding Immune Profiles in Clinical Biopsies, Monday, Apr. 16, 8 am – 12 pm, Poster Section 31, #1694.
- Comparison of Multiplexed Imaging Mass Cytometry in FFPE Tissue to Monoplex Immunohistochemistry, Tuesday, Apr. 17, 8 am – 12 pm, Poster Section 1, #3037.
- A Methodology for Designing and Validating Computational Pathology Scores for Immune Cell Clustering in Tumor Biopsies, Wednesday, Apr. 18, 8 am – 12 pm, Poster Section 31, #5684.
The American Association for Cancer Research holds the AACR Annual Meeting to bring together oncologists, laboratory scientists, medical professionals, nurses, scientists and patients together to enrich and enlighten them with the current practices and techniques in the field of cancer prevention and treatment.
Flagship’s booth, #3404, will be located on the right side of the AACR Exhibit Hall, in the first row of exhibits. Contact Flagship to schedule a meeting at AACR.
VP, Sales & Marketing